UK law firm EBITDA multiples in 2025/26 range from 0.8x for conveyancing-heavy firms in soft markets to 3x or more for specialist firms with premium positioning. Most multi-partner LLPs sit at 1.2-2.0x normalised EBITDA. The variance is enormous, and the multiple itself matters less than the normalisation work that determines the EBITDA number being multiplied.

This guide breaks down realistic multiple ranges by firm type, what's actually being normalised in "normalised EBITDA", and the strategic variables that move the multiple at the time of sale.

Realistic UK law firm EBITDA multiples — 2025/26

By firm type

  • Sole practitioner book or very small firm: 0.6-1.1x normalised EBITDA. Low scale, high key-person risk, limited buyer pool. Often valued more on revenue or fee book than EBITDA per se.
  • Small partnership or LLP (2-5 partners, £500k-£2m turnover): 1.0-1.5x. The first tier where buyer interest broadens beyond local solicitors to small consolidators.
  • Mid-market mixed LLP (5-15 partners, £2-5m turnover): 1.2-2.0x. The most active deal segment. Wide spread reflects practice area mix, growth trajectory, and partner depth.
  • Specialist firm in premium practice area: 2.0-3.0x+. Personal injury with CFA / ATE structure, prestige private client, niche commercial litigation, top-tier criminal, regulatory specialist.
  • Large LLP (15+ partners, £5m+ turnover): 1.5-2.5x typically; specialist large firms can reach 2.5-4x+. Above £20m turnover firms are usually multi-tier deal structures rather than simple EBITDA multiple.

By practice area within firm

Within a mixed-practice firm, the buyer often discounts the multiple to reflect the lowest-quality practice area exposure. A firm with 60% private client + 40% conveyancing typically gets the multiple appropriate to the conveyancing exposure, not the private client. Pure-play specialist firms in premium areas command the highest multiples because the buyer can value the full book at the premium rate.

By region

  • London (City and West End): top of the multiple range for specialist firms. Premium private client and commercial litigation firms in central London command 2.5-3.5x.
  • South East outside London: 0.05-0.15 multiple discount from equivalent London firm.
  • Other English regions: 0.15-0.30 multiple discount from London equivalent. Specialist firms in regional centres (Manchester commercial, Leeds banking, Birmingham PI) command higher multiples within their regional context.
  • Wales, Scotland, Northern Ireland: typically 0.20-0.40 discount from English regional equivalents. Smaller buyer pool, different regulatory environment in Scotland (Law Society of Scotland separate from SRA).

Normalised EBITDA — the number that actually matters

The multiple is the headline. The number being multiplied — normalised EBITDA — does most of the work in determining valuation. The normalisation adjusts the firm's reported profit for items that the post-sale buyer can't replicate or that distort the underlying earning power.

Equity partner drawings normalised to market salary

The biggest single adjustment. A post-sale buyer needs to pay someone to do the partner's fee-earning work. The cost of that replacement (a market-salary senior fee-earner, typically £80,000-£140,000 depending on practice area and region) is the real cost. Anything the partner takes above that figure is excess return on partnership equity — added back to EBITDA for valuation purposes.

Example: a senior equity partner draws £200,000 from a £3m turnover firm. Market replacement salary for the partner's fee-earning role is £110,000. Adjustment: +£90,000 to EBITDA. On a 1.5x multiple, that's +£135,000 of valuation.

Personal expenses removed

Vehicle costs not justified by business use, family employment without genuine work, club memberships unrelated to client development, partner-spouse on payroll with no defined role, hotel and meal expenses that look more like personal than business. The buyer can't continue running these costs through the firm; they're added back.

One-off items called out

PII excess on a settled claim, partner exit payment, office relocation costs, one-off litigation against the firm, single-year COVID-related costs (where still relevant). Both positive and negative one-offs are normalised — a £40,000 one-off legal cost is added back; a £25,000 one-off gain (say, lease incentive payment) is taken out.

Premises rent to a partner-owned property company adjusted to market rate. Intra-group recharges normalised. Loans from partners to the firm at non-market interest rates adjusted.

What's NOT normalised

  • Sustainable salary inflation (recurring cost)
  • Necessary technology and software costs
  • Genuine support staff costs
  • Recurring PII at normal renewal levels
  • Sustainable practising certificate and professional subscription costs

The test is: would the post-sale buyer continue this cost? If yes, it stays in EBITDA. If no, it's an add-back.

The size of the normalisation swing

Across a typical mid-market law firm sale, normalisation adjustments add 10-25 percent to reported EBITDA. On a £400k reported EBITDA, normalisation might lift it to £480k-£500k. On a 1.5x multiple, that £80-100k uplift translates to £120-150k of valuation. Far more impactful than choosing between 1.4x and 1.6x multiple.

This is why sellers who haven't been through normalisation before often see their valuation move materially once a specialist accountant works through the accounts.

What moves the multiple at the time of sale

Practice area mix

Higher-margin, lower-risk practice areas (private client, prestige commercial, regulated specialist) command premium multiples. Conveyancing-heavy and high-volume defendant work command discounts.

Growth trajectory

3-year EBITDA growth attracts a higher multiple than flat or declining EBITDA at the same current-year number. Buyers value momentum.

Partner depth

A firm with one rainmaker and several fee-earners is riskier than a firm with multiple equity partners contributing meaningfully. Key-person risk depresses the multiple — sometimes significantly. The "single seller" problem (one partner is essentially the firm) typically caps the multiple at 1.0-1.3x even for a profitable practice.

Recurring revenue mix

Retainer-based work, ongoing matter management (subscriptions, monthly billing arrangements), long-standing client relationships with high renewal probability all support higher multiples. Transactional work without repeat business attracts lower multiples.

WIP and lock-up management

Tight WIP discipline (efficient billing cycles, low aged WIP, prompt collections) signals operational quality. Bloated WIP and long lock-up signal management issues — buyers discount accordingly.

SRA compliance history

Clean SRA history attracts premium multiples. Material breach history, recent enforcement, or open SRA matters create significant deal risk and depress the multiple — sometimes prevent a deal entirely.

Corporate acquirer interest

Strategic buyers (large firms consolidating, financial buyers building portfolios) sometimes pay above market multiples for firms that fill a specific strategic gap. The premium is unpredictable — depends on the specific deal context.

The BADR rate change — why timing matters

Business Asset Disposal Relief rate rises from 14% in 2025/26 to 18% from 6 April 2026. On the £1m lifetime BADR limit, that's £40,000 of additional CGT per partner if the sale completes after 6 April 2026 instead of before.

For multi-partner sales:

  • 4-partner LLP with £1m gain each: £160,000 of additional firm-side CGT cost from completion after rate change
  • 6-partner LLP with £800k gain each: £192,000 additional CGT

This creates a real timing incentive. Firms in active sale process with completion targeted in Q1-Q2 2026 should push hard to complete before 5 April 2026 (the last day of 2025/26). Firms targeting later 2026 completion should accept that the 18% rate applies.

See our pillar guide on post-merger integration for the 90-day playbook after completion, and our law firm valuation calculator for indicative pricing on specific inputs.

Pre-sale planning — 18-24 months out

Sale-ready firms are built, not assembled. The earliest decisions move the price most:

  • Months 24 to 18 before sale: valuation refresh, BADR eligibility audit, Section 162 incorporation modelling if going share-sale route, EBITDA normalisation strategy
  • Months 18 to 12: normalisation begins to show in the accounts buyers will see, WIP discipline tightened, succession and management depth secured
  • Months 12 to 6: broker selection, marketing materials, second clean accounting period in the books
  • Months 6 to 0: live process, due diligence, completion

What we'd do if you brought us in

Our pre-sale planning engagement covers:

  • Realistic valuation on your specific firm's normalised EBITDA, practice area mix and region
  • BADR eligibility audit and timing strategy around the April 2026 rate change
  • Section 162 incorporation modelling if pre-sale incorporation is the right route
  • EBITDA normalisation in the year-ends buyers will see in due diligence
  • Co-ordination with the dental-specialist M&A broker when the time comes
  • Deal-side support during heads of terms and due diligence

If you're 12-36 months from a sale, the conversation needs to be happening now. Book a 30-minute scoping call below.